leukotriene-b4 and Pleuropneumonia

A novel series of heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids was studied as leukotriene biosynthesis inhibitors. A hypothesis of structure-activity optimization by insertion of an oxime moiety was investigated using REV-5901 as a starting point. A systematic structure-activity optimization showed that the spatial arrangement and stereochemistry of the oxime insertion unit proved to be important for inhibitory activity. The promising lead, S-(E)-11, inhibited LTB(4) biosynthesis in the intact human neutrophil with IC(50) of 8 nM and had superior oral activity in vivo, in a rat pleurisy model (ED(50) = 0.14 mg/kg) and rat anaphylaxis model (ED(50) = 0.13 mg/kg). In a model of lung inflammation, S-(E)-11 blocked LTE(4) biosynthesis (ED(50) of 0.1 mg/kg) and eosinophil influx (ED(50) of 0.2 mg/kg). S-(E)-11 (A-93178) was selected for further preclinical evaluation.

Topics: Acrylic Resins; Anaphylaxis; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Ascitic Fluid; Granuloma; Humans; In Vitro Techniques; Leukotriene B4; Male; Mice; Neutrophils; Pleuropneumonia; Pneumonia; Quinolines; Rats; Stereoisomerism; Structure-Activity Relationship